I am currently a faculty member in the Department of Biochemistry within the Boston University School of Medicine. My academic training and research experience have given me an excellent background in biochemistry, analytical chemistry (with a focus on mass spectrometry-based analyses of glycoproteins), tumor angiogenesis, and tumor biology. I completed my PhD with mentors Nathan Edwards and Radoslav Goldman at Georgetown University, where I used mass spectrometry and *in silico *methods to explore the site-specific *N*-glycosylation of Inter alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4), an acute phase protein. As a postdoc at Boston University, I have utilized mass spectrometry and molecular biology methods to study the role of glycosylation in cancer and tumor angiogenesis. As an NCI F32 Independent Research Fellowship recipient, I sought to understand how impaired glycosylation in tumor-associated endothelial cells leads to dysregulation of vascular endothelial growth factor receptor-2 (VEGFR2) pro-angiogenic signaling. During the second half of my postdoc, I have collaborated with Dr. Maria Kukuruzinksa in the BU Goldman School of Dental Medicine to show that nuclear ß-catenin/CREB-binding protein (CBP) signaling suppresses epidermal growth factor receptor (EGFR) *N*-glycan antennary fucosylation in oral cancer, leading to higher EGFR levels in oral squamous cell carcinoma (OSCC).
My long-term research interests are to pursue a mechanistic understanding of how protein glycosylation alters cellular signaling and adhesion in cancer, and to apply this knowledge to improve cancer diagnosis and treatment. The goal of my current research is to understand how *N*-glycosylation regulates (1) vascular endothelial growth factor receptor (VEGFR2) mediated angiogenic signaling in colorectal cancer, and (2) epidermal growth factor receptor (EGFR) signaling in oral squamous cell carcinoma (OSCC). My work on the role of sialic acid modifications in VEGFR2 signaling provides a key link between immune and angiogenic signaling and has been cited by leaders in angiogenesis research in *Nature Metabolism *(Carmeliet *et al.*,2019), *Mechanismsof Drug Resistance in Cancer Therapy* (Rabinovich *et al.,* 2017), and *Oncogene*(Rusnati *et al.*, 2017)
- Georgetown University, PhD
- University of Arizona, BS
- Published on 6/18/2020
Azab E, Chandler KB, Uda Y, Sun N, Hussein A, Shuwaikan R, Lu V, Costello CE, McComb ME, Divieti Pajevic P. Osteocytes control myeloid cell proliferation and differentiation through Gsa-dependent and -independent mechanisms. FASEB J. 2020 Jun 18. PMID: 32557809.
- Published on 6/14/2020
Fuzita FJ, Chandler KB, Haserick JR, Terra WR, Ferreira C, Costello CE. N-glycosylation in Spodoptera frugiperda (Lepidoptera: Noctuidae) midgut membrane-bound glycoproteins. Comp Biochem Physiol B Biochem Mol Biol. 2020 Jun 14; 110464. PMID: 32553552.
- Published on 3/23/2020
Chandler KB, Alamoud KA, Stahl VL, Nguyen BC, Kartha VK, Bais MV, Nomoto K, Owa T, Monti S, Kukuruzinska MA, Costello CE. ß-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. Mol Omics. 2020 06 01; 16(3):195-209. PMID: 32203567.
- Published on 7/15/2019
Chandler KB, Leon DR, Kuang J, Meyer RD, Rahimi N, Costello CE. N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2). J Biol Chem. 2019 08 30; 294(35):13117-13130. PMID: 31308178.
- Published on 6/5/2019
Brown Chandler K, Costello CE, Rahimi N. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells. 2019 Jun 05; 8(6). PMID: 31195728.
- Published on 1/18/2019
Chandler KB, Mehta N, Leon DR, Suscovich TJ, Alter G, Costello CE. Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles. Mol Cell Proteomics. 2019 04; 18(4):686-703. PMID: 30659065.
- Published on 6/1/2018
Ho RX, Meyer RD, Chandler KB, Ersoy E, Park M, Bondzie PA, Rahimi N, Xu H, Costello CE, Rahimi N. MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol Cell Biol. 2018 06 01; 10(3):195-204. PMID: 29329397.
- Published on 12/29/2016
Chandler KB, Leon DR, Meyer RD, Rahimi N, Costello CE. Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. J Proteome Res. 2017 Feb 03; 16(2):677-688. PMID: 27966990.
- Published on 10/31/2016
Villar RF, Patel J, Weaver GC, Kanekiyo M, Wheatley AK, Yassine HM, Costello CE, Chandler KB, McTamney PM, Nabel GJ, McDermott AB, Mascola JR, Carr SA, Lingwood D. Reconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation. Sci Rep. 2016 10 31; 6:36298. PMID: 27796362.
- Published on 3/29/2016
Chandler KB, Costello CE. Glycomics and glycoproteomics of membrane proteins and cell-surface receptors: Present trends and future opportunities. Electrophoresis. 2016 Jun; 37(11):1407-19. PMID: 26872045.
View 10 more publications: View full profile at BUMC